Sign up for our Oncology Central weekly news round-up

Gilteritinib approved in the EU for relapsed or refractory AML patients with a FLT3 mutation

Written by Jade Parker, Senior Editor

multiple myeloma

The European Commission have approved once daily Xospata™ (gilteritinib) as a monotherapy for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation.The approval follows gilteritinib receiving orphan designation by the European Medicines Agency, based on results from the Phase III ADMIRAL trial. This trial investigated patients with relapsed or refractory FLT3mut+ AML, receiving gilteritinib versus salvage chemotherapy. Key results include that patients treated with gilteritinib had significantly longer overall survival than those who received salvage chemotherapy. Additionally, the median overall survival for patients who received gilteritinib was 9.3 months, compared to 5.6...

To view this content, please register now for access

It's completely free